Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

NCT03793426 · clinicaltrials.gov ↗
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class

Stopped FORMA-07 was initiated as a requirement imposed by the U.S. FDA as part of Octapharma's regulatory obligations. After approving Fibryga for treatment of acquired fibrinogen deficiency in 2024, FDA has agreed that the study may now be discontinued.

Conditions

Interventions

Sponsor

Octapharma